For Subscribers

Get the complete article now!

INTERMUNE PHARMACEUTICALS, INC. (Nasdaq:ITMN);

Four analysts, two experts and top management from thirty-seven sector firms examine the Biotechnology sector in this special 179-page issue from The Wall Street Transcript, available at (212/952-7433) or http://www.twst.com/info/info423.htm

“InterMune has done an excellent job of in-licensing drugs. Currently, they license drugs for Connetics and ALZA, to name a few. InterMune has gone out and found value in drugs that other companies have neglected. Scott Harkonen has taken the neglected drugs and put them into new markets and for new patients. Where other companies have walked away, InterMune stuck it out and has succeeded for it. I think InterMune’s management team has been smart and made money where other companies would have failed.”

This special issue includes:

1) Biotechnology - In an in-depth (13,900 words) Analyst Roundtable, Peter Drake, Managing Director at Prudential Securities, Inc., Mary Ann Gray, Analyst focusing on both public and private healthcare investments at Federated Kaufman Fund, Michael King, Jr., Managing Director at Robertson Stephens and Elise Wang, Managing Director at Salomon Smith Barney, examine the outlook for the sector including new approaches to diseases, outlook for tools and technology companies and share specific stock recommendations.

2) Searching for Executive Leadership in Biotechnology - In an in-depth (2,600 words) Expert Interview, Robert Hennessy, Managing Director at The Hennessy Group, examines the outlook for the sector.

3) The Biotechnology Transformation - In an in-depth (2,500 words) Expert Interview, John Rhodes, Managing Partner for Pharmaceuticals and Life Sciences at Deloitte & Touche, examines the outlook for the sector.

4) The TWST confidential Off-The-Record survey of management performance at nineteen sector firms asked market insiders about the ability of management teams to create shareholder value.

5) CEO and Sponsored interviews (average 2,500 words). Top management of thirty-seven sector firms examine the outlook for their firm and the sector.